Pacira BioSciences' Total Debt rose 22.12% to $376.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $376.7 million, marking a year-over-year increase of 22.12%. This contributed to the annual value of $585.3 million for FY2024, which is 372.63% up from last year.
According to the latest figures from Q3 2025, Pacira BioSciences' Total Debt is $376.7 million, which was up 25.48% from $300.2 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Total Debt registered a high of $685.7 million during Q4 2021, and its lowest value of $109.8 million during Q2 2024.
In the last 3 years, Pacira BioSciences' Total Debt had a median value of $148.4 million in 2023 and averaged $240.9 million.
In the last 5 years, Pacira BioSciences' Total Debt tumbled by 69.52% in 2023 and then skyrocketed by 372.63% in 2024.
Quarterly analysis of 5 years shows Pacira BioSciences' Total Debt stood at $685.7 million in 2021, then plummeted by 58.48% to $284.7 million in 2022, then slumped by 56.50% to $123.8 million in 2023, then spiked by 372.63% to $585.3 million in 2024, then grew by 22.12% to $376.7 million in 2025.
Its Total Debt stands at $376.7 million for Q3 2025, versus $300.2 million for Q2 2025 and $303.6 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value